Spatial and molecular resolution of diffuse malignant mesothelioma heterogeneity by integrating label-free FTIR imaging, laser capture microdissection and proteomics
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Diffuse malignant mesothelioma (DMM) is a heterogeneous malignant neoplasia manifesting with three subtypes: epithelioid, sarcomatoid and biphasic. DMM exhibit a high degree of spatial heterogeneity that complicates a thorough understanding of the underlying different molecular processes in each subtype. We present a novel approach to spatially resolve the heterogeneity of a tumour in a label-free manner by integrating FTIR imaging and laser capture microdissection (LCM). Subsequent proteome analysis of the dissected homogenous samples provides in addition molecular resolution. FTIR imaging resolves tumour subtypes within tissue thin-sections in an automated and label-free manner with accuracy of about 85% for DMM subtypes. Even in highly heterogeneous tissue structures, our label-free approach can identify small regions of interest, which can be dissected as homogeneous samples using LCM. Subsequent proteome analysis provides a location specific molecular characterization. Applied to DMM subtypes, we identify 142 differentially expressed proteins, including five protein biomarkers commonly used in DMM immunohistochemistry panels. Thus, FTIR imaging resolves not only morphological alteration within tissue but it resolves even alterations at the level of single proteins in tumour subtypes. Our fully automated workflow FTIR-guided LCM opens new avenues collecting homogeneous samples for precise and predictive biomarkers from omics studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538 · cited 2×
“1) 36,37 .”
The Path to Personalized Medicine
Hamburg, M. A., & Collins, F. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1006304 · Cited by 1,970
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
Rifai, N., Gillette, M. A., & Carr, S. A. (2006) · Nature Biotechnology · doi:10.1038/nbt1235 · Cited by 1,867
Martens, H., & Stark, E. (1991) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/0731-7085(91)80188-f · Cited by 515
Bassan, P., Kohler, A., Martens, H., Lee, J., Byrne, H. J., Dumas, P., Gazi, E., Brown, M., Clarke, N., & Gardner, P. (2010) · The Analyst · doi:10.1039/b921056c · Cited by 375
Malignant Mesothelioma: Global Incidence and Relationship with Asbestos
BIANCHI, C., & BIANCHI, T. (2007) · Industrial Health · doi:10.2486/indhealth.45.379 · Cited by 261
Cited by
Cancer proteogenomics: current impact and future prospects
Mani, D. R., Krug, K., Zhang, B., Satpathy, S., Clauser, K. R., Ding, L., Ellis, M., Gillette, M. A., & Carr, S. A. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00446-5 · Cited by 229
Röhr, D., Boon, B. D. C., Schuler, M., Kremer, K., Hoozemans, J. J. M., Bouwman, F. H., El-Mashtoly, S. F., Nabers, A., Großerueschkamp, F., Rozemuller, A. J. M., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01091-5 · Cited by 77
Self-citationRasskazov, I. L., Spegazzini, N., Carney, P. S., & Bhargava, R. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b02168 · Cited by 20
Metadata
- Authors
- Großerueschkamp, F., Bracht, T., Diehl, H. C., Kuepper, C., Ahrens, M., Kallenbach-Thieltges, A., Mosig, A., Eisenacher, M., Marcus, K., Behrens, T., Brüning, T., Theegarten, D., Sitek, B., & Gerwert, K.
- Venue
- Scientific Reports
- Published
- 2017-03-30
- Volume
- 7
- Issue
- 1
- Pages
- 44829-44829
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2599311908
- Cited by
- 53
- References
- 6
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.